Metabolic & Endocrine · Clinical trials
Type 2 Diabetes Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About type 2 diabetes — and why its trials are hard
Type 2 diabetes (T2D) is a progressive metabolic disorder characterized by insulin resistance and relative insulin deficiency, driving chronic hyperglycemia and elevated cardiovascular, renal, and microvascular risk. Metformin remains first-line pharmacotherapy for glucose lowering, supported by decades of use and the UKPDS legacy. Management has been transformed by two agent classes proven to reduce hard outcomes beyond glycemia: SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin), which cut cardiovascular death, heart-failure hospitalization, and kidney-disease progression; and GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide), which lower HbA1c and body weight while reducing major adverse cardiovascular events. Semaglutide's SUSTAIN program and cardiovascular outcome data established GLP-1 therapy as central to modern care. The dual GIP/GLP-1 receptor agonist tirzepatide, approved in 2022 on the SURPASS program, delivered unprecedented HbA1c and weight reductions, outperforming injectable semaglutide head-to-head in SURPASS-2. Older agents (sulfonylureas, DPP-4 inhibitors, pioglitazone) retain roles, but guidelines increasingly prioritize organ-protective classes, individualized targets, and weight-centric, cardiorenal-informed treatment selection.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Tirzepatide (Mounjaro) | 2022 | Dual GIP/GLP-1 receptor agonist for glycemic control in T2D (adjunct to diet/exercise) | SURPASS program; SURPASS-2 head-to-head versus semaglutide 1 mg (NEJM 2021) | Change in HbA1c from baseline; body weight | HbA1c reductions ~2.0-2.3% and weight loss up to ~12 kg at high dose; superior to semaglutide 1 mg in SURPASS-2 |
| Semaglutide (Ozempic) | 2017 | Once-weekly GLP-1 receptor agonist for T2D; cardiovascular risk reduction | SUSTAIN program; SUSTAIN-6 cardiovascular outcomes trial (NEJM 2016) | HbA1c change; SUSTAIN-6 primary MACE composite (CV death, nonfatal MI, nonfatal stroke) | HbA1c reductions ~1.5-1.8%; SUSTAIN-6 reduced MACE by 26% (HR 0.74) versus placebo |
| Empagliflozin (Jardiance) | 2014 | SGLT2 inhibitor for T2D; later cardiovascular and kidney indications | EMPA-REG OUTCOME (NEJM 2015) | 3-point MACE composite (primary); CV death and HF hospitalization (secondary) | 38% reduction in cardiovascular death and 35% reduction in heart-failure hospitalization versus placebo |
| Metformin (Glucophage) | 1994 | First-line oral biguanide for glycemic control in T2D | UK Prospective Diabetes Study (UKPDS 34) | Diabetes-related endpoints and mortality in overweight patients | Reduced diabetes-related and all-cause mortality versus conventional therapy in overweight patients |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in type 2 diabetes development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Muraglitazar (dual PPAR-alpha/gamma agonist) — Registration/meta-analysis of Phase 3 program | Development halted; excess cardiovascular events (death, MI, stroke, heart failure) identified | Pooled analysis (JAMA 2005) showed increased CV risk; the glitazar class was abandoned for safety |
| Rosiglitazone — Meta-analysis (Nissen 2007); RECORD | Signal of increased myocardial infarction risk led to severe restrictions and market withdrawal in Europe | Cardiovascular safety concerns; regulatory response reshaped diabetes drug CV-safety requirements |
| Aleglitazar (dual PPAR agonist) — ALECARDIO (JAMA 2014) | Terminated for lack of efficacy on CV outcomes and safety signals (heart failure, renal, fractures) | No cardiovascular benefit despite improved metabolic markers; harms outweighed benefit |
Choosing the right endpoint
Primary endpoints that matter in type 2 diabetes trials
- HbA1c change from baseline — Primary glycemic efficacy endpoint across nearly all T2D registration trials
- 3-point MACE (CV death, nonfatal MI, nonfatal stroke) — Cardiovascular outcome composite mandated for modern T2D therapies
- Heart-failure hospitalization and renal composite — Key organ-protection endpoints driving SGLT2 inhibitor labeling
- Body weight change — Increasingly co-primary/secondary; central to GLP-1 and GIP/GLP-1 agents
How iNGENū runs type 2 diabetes trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Type 2 Diabetes clinical trials — FAQs
How does tirzepatide compare with semaglutide?
Why are SGLT2 inhibitors and GLP-1 agonists prioritized?
Is metformin still first-line?
Ready to discuss your type 2 diabetes trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal